123 related articles for article (PubMed ID: 9720726)
1. Syndecan-1 expression on malignant cells from the blood and marrow of patients with plasma cell proliferative disorders and B-cell chronic lymphocytic leukemia.
Witzig TE; Kimlinger T; Stenson M; Therneau T
Leuk Lymphoma; 1998 Sep; 31(1-2):167-75. PubMed ID: 9720726
[TBL] [Abstract][Full Text] [Related]
2. C-kit receptor (CD117) expression on plasma cells in monoclonal gammopathies.
Kraj M; Pogłód R; Kopeć-Szlezak J; Sokołowska U; Woźniak J; Kruk B
Leuk Lymphoma; 2004 Nov; 45(11):2281-9. PubMed ID: 15512818
[TBL] [Abstract][Full Text] [Related]
3. CD138/syndecan-1: a useful immunohistochemical marker of normal and neoplastic plasma cells on routine trephine bone marrow biopsies.
Chilosi M; Adami F; Lestani M; Montagna L; Cimarosto L; Semenzato G; Pizzolo G; Menestrina F
Mod Pathol; 1999 Dec; 12(12):1101-6. PubMed ID: 10619261
[TBL] [Abstract][Full Text] [Related]
4. Neural cell adhesion molecule expression in plasma cells in bone marrow biopsies and aspirates allows discrimination between multiple myeloma, monoclonal gammopathy of uncertain significance and polyclonal plasmacytosis.
Martín P; Santón A; Bellas C
Histopathology; 2004 Apr; 44(4):375-80. PubMed ID: 15049904
[TBL] [Abstract][Full Text] [Related]
5. The myeloma cell antigen syndecan-1 is lost by apoptotic myeloma cells.
Jourdan M; Ferlin M; Legouffe E; Horvathova M; Liautard J; Rossi JF; Wijdenes J; Brochier J; Klein B
Br J Haematol; 1998 Mar; 100(4):637-46. PubMed ID: 9531328
[TBL] [Abstract][Full Text] [Related]
6. The Mi15 monoclonal antibody (anti-syndecan-1) is a reliable marker for quantifying plasma cells in paraffin-embedded bone marrow biopsy specimens.
Costes V; Magen V; Legouffe E; Durand L; Baldet P; Rossi JF; Klein B; Brochier J
Hum Pathol; 1999 Dec; 30(12):1405-11. PubMed ID: 10667416
[TBL] [Abstract][Full Text] [Related]
7. Autocrine interleukin-6 production and highly malignant multiple myeloma: relation with resistance to drug-induced apoptosis.
Frassanito MA; Cusmai A; Iodice G; Dammacco F
Blood; 2001 Jan; 97(2):483-9. PubMed ID: 11154226
[TBL] [Abstract][Full Text] [Related]
8. Soluble syndecan-1 levels in different plasma cell dyscrasias and in different stages of multiple myeloma.
Jánosi J; Sebestyén A; Mikala G; Németh J; Kiss Z; Vályi-Nagy I
Haematologica; 2004 Mar; 89(3):370-1. PubMed ID: 15020284
[TBL] [Abstract][Full Text] [Related]
9. Syndecan-1 (CD138) immunoreactivity in bone marrow biopsies of multiple myeloma: shed syndecan-1 accumulates in fibrotic regions.
Bayer-Garner IB; Sanderson RD; Dhodapkar MV; Owens RB; Wilson CS
Mod Pathol; 2001 Oct; 14(10):1052-8. PubMed ID: 11598177
[TBL] [Abstract][Full Text] [Related]
10. Syndecan-1 in B lymphoid malignancies.
Sanderson RD; Børset M
Ann Hematol; 2002 Mar; 81(3):125-35. PubMed ID: 11904737
[TBL] [Abstract][Full Text] [Related]
11. Syndecan-1 and angiogenic cytokines in multiple myeloma: correlation with bone marrow angiogenesis and survival.
Andersen NF; Standal T; Nielsen JL; Heickendorff L; Borset M; Sørensen FB; Abildgaard N
Br J Haematol; 2005 Jan; 128(2):210-7. PubMed ID: 15638855
[TBL] [Abstract][Full Text] [Related]
12. [Soluble syndecan-1 levels in different plasma cell dyscrasias].
Jánosi J; Sebestyén A; Mikala G; Petö M; Jákó J; Domján G; Németh J; Kis Z; Kopper L; Vályi-Nagy I
Orv Hetil; 2005 Jan; 146(4):165-8. PubMed ID: 15751511
[TBL] [Abstract][Full Text] [Related]
13. Chromosomal aberrations are shared by malignant plasma cells and a small fraction of circulating CD19+ cells in patients with myeloma and monoclonal gammopathy of undetermined significance.
Zojer N; Schuster-Kolbe J; Assmann I; Ackermann J; Strasser K; Hübl W; Drach J; Ludwig H
Br J Haematol; 2002 Jun; 117(4):852-9. PubMed ID: 12060120
[TBL] [Abstract][Full Text] [Related]
14. Syndecan-1 (CD138) expression in human non-Hodgkin lymphomas.
Sebestyén A; Berczi L; Mihalik R; Paku S; Matolcsy A; Kopper L
Br J Haematol; 1999 Feb; 104(2):412-9. PubMed ID: 10050727
[TBL] [Abstract][Full Text] [Related]
15. RAS mutations are uncommon in multiple myeloma and other monoclonal gammopathies.
Martín P; Santón A; García-Cosío M; Bellas C
Int J Oncol; 2005 Oct; 27(4):1023-8. PubMed ID: 16142319
[TBL] [Abstract][Full Text] [Related]
16. Flow cytometric evaluation of bone marrow plasma cells using CD19, CD45, CD56, CD38, and CD138 and correlation with bone marrow infiltration ratio in multiple myeloma patients.
Kara IO; Sahin B; Paydas S; Cetiner S
Saudi Med J; 2004 Nov; 25(11):1587-92. PubMed ID: 15573184
[TBL] [Abstract][Full Text] [Related]
17. Serum syndecan-1 in patients with newly diagnosed monoclonal proteinemia.
Schaar CG; Vermeer HJ; Wijermans PW; Huisman W; le Cessie S; Kluin-Nelemans HC
Haematologica; 2005 Oct; 90(10):1437-8. PubMed ID: 16219583
[TBL] [Abstract][Full Text] [Related]
18. Evidence of a role for a non-matrix-type metalloproteinase activity in the shedding of syndecan-1 from human myeloma cells.
Holen I; Drury NL; Hargreaves PG; Croucher PI
Br J Haematol; 2001 Aug; 114(2):414-21. PubMed ID: 11529866
[TBL] [Abstract][Full Text] [Related]
19. Soluble syndecan-1 promotes growth of myeloma tumors in vivo.
Yang Y; Yaccoby S; Liu W; Langford JK; Pumphrey CY; Theus A; Epstein J; Sanderson RD
Blood; 2002 Jul; 100(2):610-7. PubMed ID: 12091355
[TBL] [Abstract][Full Text] [Related]
20. Expression of syndecan-1 in human B cell chronic lymphocytic leukaemia.
Sebestyén A; Kovalszky I; Mihalik R; Gallai M; Bocsi J; László E; Benedek S; Sréter L; Kopper L
Eur J Cancer; 1997 Nov; 33(13):2273-7. PubMed ID: 9470818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
